rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SMMT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Summit cut to Underperform at Bernstein on R&D capabilities

      Summit Therapeutics (SMMT) stock slips as Bernstein downgrades the company to Underperform from Market Perform, citing concern over its R&D efforts. Read more here.

      9h agoSeeking AlphaSMMT
      Summit Therapeutics (SMMT) Is Losing Wall Street’s Confidence
      20h agoYahoo FinanceSMMT
      Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug

      The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.

      Nov 17MarketWatchSMMT
      Summit Therapeutics (SMMT) Stock Sees Modest Fair Value Cut As Analysts Weigh Trial Risks

      Summit Therapeutics has seen its modeled fair value per share edge down from US$30.07 to US$29.41, which gives you an updated reference point for where some analysts see long term worth. This subtle shift lines up with recent research that weighs the US$2b AstraZeneca partnership and lung cancer program optimism against questions on valuation, trial outcomes, and competitive pressures. As you read on, you will see how these moving targets shape the evolving analyst story around Summit...

      Nov 17Yahoo FinanceSMMT
      The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.

      The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

      Nov 16MarketWatchSMMT
      Summit Therapeutics: Still A Hold As The 2L Gamble Fails And 1L Data Looms

      Summit Therapeutics remains a 'Hold': U.S. translation risk and approaching HARMONi-3 data make ivonescimab a binary bet. Click to read more on SMMT stock.

      Nov 16Seeking AlphaSMMT
      Why Is Summit Therapeutics (SMMT) Facing An FDA Setback For Ivonescimab?
      Nov 16Yahoo FinanceSMMT
      Summit Therapeutics stock hits 52-week low at $12.04
      Nov 16Investing.comSMMT
      SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter
      Nov 16Yahoo FinanceSMMT
      FDA Rejects Summit's China-Developed Merck Rival; Shares Dive

      Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug.

      Nov 16Investor's Business DailySMMTMRK
      Nvidia, Sandisk, SpaceX, L3Harris, Strategy, Summit Therapeutics, and More Stocks That Explain Today’s Market
      Nov 16Barron'sINTCNVDASMMTSNDKSPCXLHXTSN
      Summit’s FDA Setback Is a Reality Check for Next-Gen Cancer Drugs

      Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.

      Nov 16Barron'sAZNSMMT
      Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
      Nov 16BenzingaACRSSMMT
      Breakfast News: Summit’s FDA Setback Isn’t the End | The Motley Fool

      Summit falls on cancer drug approval setback, Nvidia headlines the week’s earnings, and more…

      Nov 16The Motley FoolSMMT
      Why Is Summit Therapeutics Stock Plunging Today? - Summit Therapeutics (NASDAQ:SMMT)
      Nov 16BenzingaSMMT
      Summit shares drop after US FDA declines to approve lung cancer drug
      Nov 16ReutersSMMT
      Summit Therapeutics stock plunges after FDA rejects lung cancer drug
      Nov 16Investing.comSMMT
      Why is Summit Therapeutics stock plunging today?
      Nov 16Investing.comSMMT
      F.D.A. Rejects Closely Watched Lung Cancer Drug From China

      The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.

      Nov 15The New York TimesSMMT
      FDA Doesn't Approve Summit's Lung Cancer Drug From China

      The FDA said Summit's ivonescimab didn't show a significant survival benefit.

      Nov 15Investor's Business DailySMMT
      FDA declines approval of Summit’s lung cancer treatment

      Summit Therapeutics says FDA declines ivonescimab plus chemotherapy approval for advanced lung cancer, citing insufficient evidence of longer survival.

      Nov 15Seeking AlphaSMMT
      FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector
      Nov 15Financial TimesSMMT
      Jefferies reiterates Summit Therapeutics stock rating after FDA setback
      Nov 15Investing.comSMMT
      US FDA Rejects Summit’s China-Originated Lung Cancer Drug
      Nov 15BloombergSMMT
      US FDA declines to approve Summit lung cancer drug after trial misses key survival goal
      Nov 15ReutersSMMT
      Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
      Nov 15Yahoo FinanceSMMT
      Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?
      Nov 10Yahoo FinanceSMMT
      Summit Therapeutics (SMMT) Stock Looks Richly Priced On Its 7x Run
      Nov 10Yahoo FinanceSMMT
      Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
      Nov 9BenzingaSMMTHIMSLLY
      FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
      Nov 9Yahoo FinanceCYTKSMMTTEVA
      Stifel cuts Summit Therapeutics stock price target on valuation
      Nov 5Investing.comSMMT
      Summit Therapeutics files legal opinion for common stock issuance
      Nov 4Investing.comSMMT
      Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
      Nov 4Yahoo FinanceSMMT
      Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI Deal
      Oct 30Yahoo FinanceSMMT
      Summit Therapeutics stock rating reaffirmed at Citizens on trial data
      Oct 27Investing.comSMMT
      Jefferies reiterates Buy on Summit Therapeutics stock, $30 target
      Oct 26Investing.comSMMT
      Stifel reiterates Buy on Summit Therapeutics stock on trial data
      Oct 26Investing.comSMMTSF
      Lunit and Summit to evaluate pathology platform for tumour analysis
      Oct 26Yahoo FinanceSMMT
      Summit Therapeutics reports survival benefit for cancer drug in trial (SMMT:NASDAQ)
      Oct 25Seeking AlphaSMMT
      Summit Therapeutics partners with Lunit on AI pathology research
      Oct 23Investing.comSMMT
      Summit Expands Ivonescimab Development Into Biliary Tract Cancer
      Oct 22Yahoo FinanceSMMT
      Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
      Oct 21Yahoo FinanceSMMT
      Summit Therapeutics begins biliary tract cancer trial for ivonescimab
      Oct 21Investing.comSMMT
      Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
      Oct 21Yahoo FinanceSMMT
      Summit Therapeutics to Collaborate With ECOG-ACRIN Cancer Research Group to Test Bile Duct Cancer Drug
      Oct 21Yahoo FinanceSMMT
      Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

      MIAMI, October 21, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab pl

      Oct 21Yahoo FinanceSMMT
      Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
      Oct 19Yahoo FinanceSMMT
      Summit Therapeutics Initiates Phase 2 Study of Ivonescimab in Kidney Cancer
      Oct 19Yahoo FinanceSMMT
      Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus
      Oct 17Yahoo FinanceAZNSMMT
      AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

      Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.

      Oct 5CNBCAZNSMMT

      This is the newest page. Registered accounts read further back.